Urologix, Inc. (ULGX) Research

Established in 1991 and headquartered in Minneapolis, Minnesota, Urologix, Inc. specializes in the development, production, promotion, and distribution of minimally invasive medical devices across the United States. The company's innovative solutions target the treatment of obstructions and related symptoms caused by benign prostatic hyperplasia (BPH). Among its key offerings is Cooled ThermoTherapy, a system that precisely applies microwave energy while simultaneously employing a cooling mechanism to safeguard healthy tissues and improve patient comfort. Urologix also provides the Prostiva RF Therapy System, which directs radio frequency energy into the prostate gland. This process works to eliminate problematic prostatic tissue, consequently easing urethral constriction and alleviating BPH-related discomfort. Urologix, Inc. caters to both healthcare professionals and patients.

Open Urologix, Inc. (ULGX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.